Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 44

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 44
---
 found liable for monetary damages, including treble damages and attorneys’ fees if we are found to have
willfully infringed a patent. A finding of infringement could force us to cease some of our business operations, which could materially
harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar
negative impact on our business. Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes
the market price of our Ordinary Shares to decline.

Because competition in our
industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or other intellectual
property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time
consuming, and could distract our technical and management personnel from their normal responsibilities. Any claims we assert against
perceived infringers could provoke these parties to assert counterclaims or file administrative actions against us alleging that we infringe
their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable,
in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue
on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding or administrative
action could put one or more of our patents at risk of being invalidated or interpreted narrowly. Our competitors may assert invalidity
on various grounds, including lack of novelty, obviousness or that we were not the first applicant to file a patent application related
to our product. We may elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes before
litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because
of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our
confidential information could be compromised by disclosure.

Our competitors, many of which
have made substantial investments in patent portfolios, trade secrets, trademarks and competing technologies, may have applied for or
obtained, or may in the future apply for or obtain, patents or trademarks that may prevent, limit or otherwise interfere with our ability
to make, use, sell and/or export our products or to use our technologies or product names. Moreover, individuals and groups that are non-practicing
entities, commonly referred to